Biodesix vs Cryo Cell International
Biodesix reported revenue of $88 million in fiscal 2025, 2.8 times Cryo Cell International's $32 million in fiscal 2025. Biodesix's revenue grew 24.1% in its latest year, and Cryo Cell International's fell 1.3%. Biodesix had an operating margin of -31.5%, against 1.5% at Cryo Cell International. Free cash flow was −$24 million at Biodesix and $5 million at Cryo Cell International. Their fiscal years end in different months (December 31 and November 30), so the periods don't line up exactly.
Side by side
| Biodesix | Cryo Cell International | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Nov 30, 2025 |
| Revenue | $88M | $32M |
| Revenue growth | 24.1% | −1.3% |
| Revenue growth a year, last 5 years | 14.2% | 0.3% |
| Gross margin | — | 76.6% |
| Operating margin | −31.5% | 1.5% |
| Net margin | −39.9% | −7.7% |
| Free cash flow | −$24M | $5M |
| Free cash flow margin | −26.6% | 16.6% |
| Return on capital | −69.7% | — |
| Net debt to EBITDA | — | 3.5x |
| Dividends and buybacks | $0M | $3M |
| Change in diluted share count | 16.7% | −1.8% |
| Last close | $8.30 | $4.15 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $3.1 million, sold $104,401 | — |
| Piotroski F-score | 3 of 8 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BiodesixCryo Cell International
Operating margin
Percent of revenue
BiodesixCryo Cell International
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BiodesixCryo Cell International
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Biodesix and Cryo Cell International pages.